Cosmos Health Inc. - COSM STOCK NEWS

Cosmos Health's subsidiary, Cana Laboratories, has signed a contract manufacturing agreement with Australian wellness company Humacology. The agreement entails producing up to 500,000 units of CBD products annually. This is the second major deal for Cana in a week, following a similar agreement with Provident Pharmaceuticals for 4.32 million units of DE3-SOLE. Humacology, known for high-quality CBD therapies and medicinal cannabis, is expanding globally and has chosen Cana for its manufacturing needs. CEO of Cosmos, Greg Siokas, highlighted the company's rapid growth in high-margin contract manufacturing and hinted at more upcoming agreements.

Cosmos Health has enhanced and expanded its strategic collaboration with C.A. Papaellinas Group in Cyprus. The collaboration, originally announced on September 20, 2023, has led to the sale of 68,000 units of Sky Premium Life products. The company now projects sales will more than double to 150,000 units within the next 12 months due to increased market penetration.

Papaellinas, a leading distributor in Cyprus, represents brands like Panadol, Sensodyne, and Adidas, and operates retail chains including Holland & Barrett. The expansion aims to increase sales and explore additional opportunities beyond the current product line. CEO Greg Siokas expressed satisfaction with the partnership and the positive market reception.

Cosmos Health's subsidiary, Cana Laboratories, has finalized significant facility upgrades, enhancing its production capabilities.

In tandem, Cana secured a contract manufacturing agreement with Provident Pharmaceuticals to produce 4.32 million vials of DE3-SOLE, a key pharmaceutical product. This strategic partnership is expected to bolster Cosmos Health's market position and revenue streams.

The facility upgrades aim to improve operational efficiency and meet increasing demand, while the large-scale contract underscores Cana's manufacturing prowess and Provident's trust in their capabilities.

The agreement reflects a significant milestone for Cosmos Health, potentially driving robust financial growth and enhancing shareholder value.

Cosmos Health announced a distribution agreement with ZENDON for its Sky Premium Life nutraceutical products in Slovakia, Hungary, Poland, and Czechia. The agreement will leverage Zendon's existing partnerships with leading pharmacy and retail chains, providing access to over 6,000 stores. This strategic move aims to gain market share in Central and Eastern Europe, with major partners including Dr. Max, Teta Drogerie, and Rossmann. CEO Greg Siokas highlighted the company's commitment to expanding its global footprint and achieving sustained profitability.

Cosmos Health announced an exclusive distribution agreement with Pharmalink to market its Sky Premium Life nutraceuticals in the UAE. Pharmalink, a leading UAE healthcare organization, will manage sales, marketing, logistics, and distribution functions. Cosmos has received an initial order of 130,000 units and forecasts sales of over 500,000 units in the first year and more than 3 million units over the next five years. Pharmalink's CEO, Dr. Abdul Rauf Jabour, and Cosmos Health's CEO, Greg Siokas, expressed optimism about the partnership's potential to penetrate the UAE nutritional supplements market.

Cosmos Health (NASDAQ:COSM) announced its agreement to acquire the remaining rights to a CNS cancer drug patent filed with WIPO under PCT/EP2023/071865. This acquisition follows the December 2023 agreement where Cosmos Health had secured 60% of the rights. The National Hellenic Research Foundation, a major Greek research entity, will continue supporting Cosmos Health during the transition. This move aims to bolster Cosmos Health's position in the global brain tumor treatment market, projected to grow from $3.1 billion in 2023 to $6.2 billion by 2033. CEO Greg Siokas highlighted the importance of this acquisition in addressing the rising incidence of CNS cancers and the needs of the aging population. This initiative is complemented by recent hires and the strategic acquisition of Cloudpharm to enhance R&D capabilities with AI-aided drug repurposing technologies.

Cosmos Health (NASDAQ:COSM), a global healthcare group, has acquired Pelofarm's pharmacy distribution network in Arcadia, Greece. This strategic move is expected to boost Cosmos Health's annual revenue by over $5 million. The acquisition, through CosmoFarm Pharmaceuticals, expands their reach to more than 30 pharmacies, with plans to add 20 more in the region. This follows their recent acquisitions of Bikas GP and Pharmatrade, aiming to increase total annual revenue by over $15 million. CEO Greg Siokas highlighted the importance of this acquisition for sustained profitability and market share growth.

On May 21, 2024, Cosmos Health received an additional delinquency letter from Nasdaq for failing to file its Form 10-Q for Q1 2024 and its Annual Report on Form 10-K for 2023.

The initial failure notice was issued on April 17, 2024, giving the company until June 17, 2024, to submit a plan to regain compliance. If Nasdaq accepts the plan, Cosmos Health could get an extension until October 14, 2024, to meet the compliance requirements. Failure to comply could result in delisting, but the company's shares remain listed for now.

CEO Greg Siokas expressed confidence in regaining compliance. The situation could impact investor confidence and stock performance (NASDAQ: COSM).

Cosmos Health (NASDAQ:COSM) announced its successful participation in Vitafoods Europe 2024, held from May 14 to May 16 at Palexpo, Switzerland. The event, a premier nutraceutical trade show, attracted over 20,000 attendees, more than 50 speakers, and 1,100+ exhibitors from 160+ countries. Cosmos Health showcased its Sky Premium Life nutraceuticals range, receiving significant interest and positive feedback from industry leaders and potential partners. The company connected with numerous organizations, exploring new trends and building partnerships to expand its global business network. CEO Greg Siokas highlighted the event's success in accelerating business growth and enhancing Cosmos Health's international presence.